Literature DB >> 18566123

Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection.

Kun Don Yi1, James W Simpkins.   

Abstract

It is becoming increasingly clear that protein phosphatases are important modulators of cellular function and that disruption of these proteins are involved in neurodegenerative disease processes. Serine/threonine protein phosphatases (PP) such as protein phosphatase PP1, PP2A, and calcineurin are involved in hyperphosphorylation of tau- as well as beta-amyloid-induced cell death. We have previously shown serine/threonine protein phosphatases to be involved in estrogen-mediated neuroprotection. The purpose of this study was to delineate the role of PP1, PP2A, and calcineurin in the mechanism of estrogen mediated neuroprotection against oxidative stress and excitotoxicity. Treatment with protein phosphatases inhibitor II, endothall, or cyclosporin A, which are specific inhibitors of PP1, PP2A, and calcineurin, respectively, did not have an effect on cell viability. However, in combination, these inhibitors adversely affected cell survival, which suggests the importance of serine/threonine protein phosphatases in maintenance of cellular function. Inhibitors of PP1, PP2A, and calcineurin attenuated the protective effects of estrogen against glutamate-induced -neurotoxicity but did not completely abrogate the estrogen-mediated protection. The attenuation of estrogen-induced neuroprotection was achieved through decrease in the activity of theses serine/threonine phosphatases without the concomitant decrease in protein expression. In an animal model, transient middle cerebral artery occlusion caused a 50% decrease in levels of PP1, PP2A, and PP2B ipsilateral to the lesion in a manner that was prevented by estradiol pretreatment. Therefore, we conclude that in the face of cytotoxic challenges in vitro and in vivo, estrogens maintain the function of PP1, PP2A, and calcineurin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566123      PMCID: PMC2582922          DOI: 10.1210/en.2008-0610

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  67 in total

Review 1.  Failure of the ubiquitin-proteasome system in Parkinson's disease.

Authors:  K S McNaught; C W Olanow; B Halliwell; O Isacson; P Jenner
Journal:  Nat Rev Neurosci       Date:  2001-08       Impact factor: 34.870

2.  Estradiol exerts neuroprotective effects when administered after ischemic insult.

Authors:  S H Yang; J Shi; A L Day; J W Simpkins
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

3.  Impaired proteasome function in Alzheimer's disease.

Authors:  J N Keller; K B Hanni; W R Markesbery
Journal:  J Neurochem       Date:  2000-07       Impact factor: 5.372

4.  The pathogenesis of cell death in Parkinson's disease.

Authors:  Peter Jenner; C Warren Olanow
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

5.  Cantharidin-binding protein: identification as protein phosphatase 2A.

Authors:  Y M Li; J E Casida
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.

Authors:  Joungil Choi; Allan I Levey; Susan T Weintraub; Howard D Rees; Marla Gearing; Lih-Shen Chin; Lian Li
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

7.  Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type.

Authors:  T Ohkura; K Isse; K Akazawa; M Hamamoto; Y Yaoi; N Hagino
Journal:  Endocr J       Date:  1994-08       Impact factor: 2.349

8.  Postmenopausal oestrogen treatment and stroke: a prospective study.

Authors:  A Paganini-Hill; R K Ross; B E Henderson
Journal:  BMJ       Date:  1988 Aug 20-27

9.  Transcriptional suppression of estrogen receptor gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Authors:  Y Tian; S Ke; T Thomas; R J Meeker; M A Gallo
Journal:  J Steroid Biochem Mol Biol       Date:  1998-10       Impact factor: 4.292

10.  Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues.

Authors:  Y M Li; C Mackintosh; J E Casida
Journal:  Biochem Pharmacol       Date:  1993-10-19       Impact factor: 5.858

View more
  10 in total

1.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

2.  Mechanism of okadaic acid-induced neuronal death and the effect of estrogens.

Authors:  Kun Don Yi; Douglas F Covey; James W Simpkins
Journal:  J Neurochem       Date:  2008-11-28       Impact factor: 5.372

Review 3.  Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application.

Authors:  Pradip K Kamat; Shivika Rai; Supriya Swarnkar; Rakesh Shukla; Chandishwar Nath
Journal:  Mol Neurobiol       Date:  2014-04-08       Impact factor: 5.590

Review 4.  Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens.

Authors:  James W Simpkins; Kun Don Yi; Shao-Hua Yang
Journal:  Front Neuroendocrinol       Date:  2009-05-03       Impact factor: 8.606

Review 5.  Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications.

Authors:  Jin-Qiang Chen; Patrick R Cammarata; Christopher P Baines; James D Yager
Journal:  Biochim Biophys Acta       Date:  2009-06-23

6.  Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.

Authors:  Monica Mann; Valerie Cortez; Ratna K Vadlamudi
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

7.  Protein phosphatase 1 dephosphorylates profilin-1 at Ser-137.

Authors:  Jieya Shao; Marc I Diamond
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

Review 8.  Protective actions of 17β-estradiol and progesterone on oxidative neuronal injury induced by organometallic compounds.

Authors:  Yasuhiro Ishihara; Takuya Takemoto; Atsuhiko Ishida; Takeshi Yamazaki
Journal:  Oxid Med Cell Longev       Date:  2015-03-01       Impact factor: 6.543

Review 9.  A Review of Calcineurin Biophysics with Implications for Cardiac Physiology.

Authors:  Ryan B Williams; Christopher N Johnson
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

10.  Upregulation of protein phosphatase 2A and NR3A-pleiotropic effect of simvastatin on ischemic stroke rats.

Authors:  Minxia Zhu; Jin Wang; Min Liu; Dongshu Du; Chunmei Xia; Linlin Shen; Danian Zhu
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.